Genentech’s Plan To Restrict Avastin Under Scrutiny

Law360, New York (November 30, 2007, 12:00 AM EST) -- A U.S. senator is investigating Genentech Inc.’s proposed plan to limit the availability of its cancer drug Avastin to certain pharmaceutical compounding firms and pharmacies.

In letters made public Nov. 28, U.S. Senate Special Committee on Aging Chairman Herb Kohl (D-Wisc.) revealed that he has authorized his staff to make inquiries concerning the circumstances surrounding Genentech’s announced partial withdrawal of Avastin from the marketplace.

The letters referenced an Oct. 12 article in the Wall Street Journal which reported that because Medicare is a large purchaser of...
To view the full article, register now.